<DOC>
	<DOC>NCT01959243</DOC>
	<brief_summary>To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric subjects. At least 51% of subjects will be 40 years of age or older.</brief_summary>
	<brief_title>Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.</brief_title>
	<detailed_description />
	<mesh_term>Hyperemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Participants must be at least 5 years of age at Visit 1 of either sex gender and any race or ethnicity; Have ocular health within normal limits, including a calculated best corrected (if necessary) visual acuity of 0.3 logMAR or better in each eye, as measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Have any ocular/systemic health problems Use of any disallowed medications during the period indicated prior to Visit 1 and for the duration of the study.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Ocular redness</keyword>
</DOC>